# Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)

> **NCT05618301** · PHASE1 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 10 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Motixafortide
- **DRUG:** Natalizumab
- **PROCEDURE:** Leukapheresis

## Key facts

- **NCT ID:** NCT05618301
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-07
- **Primary completion:** 2025-06-24
- **Final completion:** 2025-06-24
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2025-08-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05618301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05618301, "Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05618301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*